# C_2011264EN.01002501.xml

| 8.9.2011 | EN | Official Journal of the European Union | C 264/25 |
| --- | --- | --- | --- |

8.9.2011

EN

Official Journal of the European Union

C 264/25

---

Prior notification of a concentration

(Case COMP/M.6280 — Procter & Gamble/Teva OTC business)

(Text with EEA relevance)

2011/C 264/14

| 1. | On 26 August 2011, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking ‘The Procter & Gamble Company’ (USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of parts of the OTC business of Teva Pharmaceutical Industries Ltd (Israel) by way of acquiring shares in a newly created company to which both parties will contribute assets. |
| --- | --- |

1.

On 26 August 2011, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking ‘The Procter & Gamble Company’ (USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of parts of the OTC business of Teva Pharmaceutical Industries Ltd (Israel) by way of acquiring shares in a newly created company to which both parties will contribute assets.

1

| 2. | The business activities of the undertakings concerned are:






  — | for The Procter & Gamble Company: Beauty and health care, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for The Procter & Gamble Company: Beauty and health care,

| — | for Teva Pharmaceutical Industries Ltd: Manufacture of pharmaceutical preparations. |
| --- | --- |

—

for Teva Pharmaceutical Industries Ltd: Manufacture of pharmaceutical preparations.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6280 — Procter & Gamble/Teva OTC business, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6280 — Procter & Gamble/Teva OTC business, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

1

---